159 related articles for article (PubMed ID: 29625929)
1. Thiotepa 10 mg/kg Treatment Regimen Is Superior to Thiotepa 5 mg/kg in TBF Conditioning in Patients Undergoing Allogeneic Stem-Cell Transplantation.
El-Cheikh J; Massoud R; Moukalled N; Haffar B; Assi H; Zahreddine A; Mahfouz R; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):368-374. PubMed ID: 29625929
[TBL] [Abstract][Full Text] [Related]
2. Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Eder S; Canaani J; Beohou E; Labopin M; Sanz J; Arcese W; Or R; Finke J; Cortelezzi A; Beelen D; Passweg J; Socié G; Gurman G; Aljurf M; Stelljes M; Giebel S; Mohty M; Nagler A
Am J Hematol; 2017 Oct; 92(10):997-1003. PubMed ID: 28614903
[TBL] [Abstract][Full Text] [Related]
3. Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation.
Picardi A; Fabritiis Pd Pd; Cudillo L; Dentamaro T; Cupelli L; Ballatore G; Venditti A; Caravita T; Cristina Cox M; Catalano G; Amadori S
Hematol J; 2004; 5(1):24-31. PubMed ID: 14745426
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
6. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies.
Alessandrino EP; Bernasconi P; Colombo AA; Caldera D; Malcovati L; Troletti D; Vanelli L; Varettoni M; Montanari F; Lazzarino M
Bone Marrow Transplant; 2004 Dec; 34(12):1039-45. PubMed ID: 15516936
[TBL] [Abstract][Full Text] [Related]
7. A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin.
Larsen JT; Hogan WJ; Micallef IN; Dispenzieri A; Gertz MA; Inwards DJ; Tun HW; Roy V; Geyer SM; Allred JB; Wu W; Ansell SM; Elliott MA; Tefferi A; Porrata LF; Gastineau DA; Lacy MQ; Litzow MR
Leuk Lymphoma; 2013 Aug; 54(8):1713-8. PubMed ID: 23189958
[TBL] [Abstract][Full Text] [Related]
8. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
[TBL] [Abstract][Full Text] [Related]
9. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.
Sanz J; Boluda JC; Martín C; González M; Ferrá C; Serrano D; de Heredia CD; Barrenetxea C; Martinez AM; Solano C; Sanz MA; Sanz GF;
Bone Marrow Transplant; 2012 Oct; 47(10):1287-93. PubMed ID: 22327127
[TBL] [Abstract][Full Text] [Related]
10. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
11. Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Eder S; Labopin M; Arcese W; Or R; Majolino I; Bacigalupo A; de Rosa G; Volin L; Beelen D; Veelken H; Schaap NP; Kuball J; Cornelissen J; Nagler A; Mohty M;
Eur J Haematol; 2016 Jan; 96(1):90-7. PubMed ID: 25807864
[TBL] [Abstract][Full Text] [Related]
12. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
[TBL] [Abstract][Full Text] [Related]
13. Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
Baronciani D; Depau C; Targhetta C; Derudas D; Culurgioni F; Tandurella I; Latte G; Palmas A; Angelucci E
Hematol Oncol; 2016 Mar; 34(1):17-21. PubMed ID: 25626861
[TBL] [Abstract][Full Text] [Related]
14. Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors.
Duléry R; Ménard AL; Chantepie S; El-Cheikh J; François S; Delage J; Giannotti F; Ruggeri A; Brissot E; Battipaglia G; Malard F; Belhocine R; Sestili S; Vekhoff A; Delhommeau F; Reman O; Legrand O; Labopin M; Rubio MT; Mohty M
Biol Blood Marrow Transplant; 2018 May; 24(5):1013-1021. PubMed ID: 29337223
[TBL] [Abstract][Full Text] [Related]
15. Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia-A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Eder S; Beohou E; Labopin M; Sanz J; Finke J; Arcese W; Or R; Bonifazi F; Aljurf M; Socié G; Passweg J; Giebel S; Mohty M; Nagler A
Am J Hematol; 2017 Jan; 92(1):18-22. PubMed ID: 27673280
[TBL] [Abstract][Full Text] [Related]
16. Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.
Peterlin P; Delaunay J; Guillaume T; Gastinne T; Mahé B; Dubruille V; Blin N; Le Bourgeois A; Brissot E; Lodé L; Le Gouill S; Moreau P; Mohty M; Chevallier P
Biol Blood Marrow Transplant; 2015 Jan; 21(1):180-4. PubMed ID: 25175796
[TBL] [Abstract][Full Text] [Related]
17. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
van Besien K; Devine S; Wickrema A; Jessop E; Amin K; Yassine M; Maynard V; Stock W; Peace D; Ravandi F; Chen YH; Cheung T; Vijayakumar S; Hoffman R; Sosman J
Bone Marrow Transplant; 2003 Jul; 32(1):9-13. PubMed ID: 12815472
[TBL] [Abstract][Full Text] [Related]
18. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Raiola AM; Dominietto A; Ghiso A; Di Grazia C; Lamparelli T; Gualandi F; Bregante S; Van Lint MT; Geroldi S; Luchetti S; Ballerini F; Miglino M; Varaldo R; Bacigalupo A
Biol Blood Marrow Transplant; 2013 Jan; 19(1):117-22. PubMed ID: 22940057
[TBL] [Abstract][Full Text] [Related]
19. Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma.
Majolino I; Davoli M; Carnevalli E; Locasciulli A; Di Bartolomeo P; Scimè R; Corradini P; Selleri C; Narni F; Musso M; Bregni M; Olivieri A; De Fabritiis P; Pogliani L; Arbelaez JE; Ruscio C; Bacigalupo A;
Leuk Lymphoma; 2007 Apr; 48(4):759-66. PubMed ID: 17454635
[TBL] [Abstract][Full Text] [Related]
20. Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Al Malki MM; Nathwani N; Yang D; Armenian S; Dadwal S; Salman J; Mokhtari S; Cao T; Sandhu K; Rouse M; Mei M; Ali H; Parker P; Alvarnas J; Smith E; Donnell MO; Marcucci G; Snyder D; Nademanee A; Forman SJ; Stein A; Nakamura R
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1828-1835. PubMed ID: 29753158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
